LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
Jean Bourhis(University of Lausanne), A. Aupérin(Inserm), Christian Borel(Centre Hospitalier de Bretagne Sud), C. Even(Institut Gustave Roussy), X. Liem(Centre Oscar Lambret), E. Saâda-Bouzid(Centre Antoine Lacassagne), Laura Sinigaglia(Groupe d'Oncologie Radiothérapie Tête et Cou), Y. Pointreau(Centre Hospitalier Universitaire de Nantes), Yungan Tao(Université Paris-Saclay), Clément Sire(Centre National de la Recherche Scientifique), M.-C. Kaminsky(Institut de Cancérologie de Lorraine), J. Miroir(Centre Jean Perrin), Juliette Thariat(Centre National de la Recherche Scientifique), Laurent Martin(Groupe Hospitalier du Havre), Aline Maillard(Institut Gustave Roussy), Xiaonan Sun(Sir Run Run Shaw Hospital), A. Coutte(Centre Hospitalier Universitaire Amiens-Picardie), F. Rolland(Institut de Cancérologie de l'Ouest), J. Guigay(Centre Antoine Lacassagne)
Cited by 87
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806